Correlates of Continued Tobacco Use and Intention to Quit Smoking Among Russian Cancer Patients

Department of Psychiatry, University of Pennsylvania, 3535 Market Street, 4th Floor, Philadelphia, PA 19104, USA.
International Journal of Behavioral Medicine (Impact Factor: 2.63). 11/2010; 18(4):325-32. DOI: 10.1007/s12529-010-9131-8
Source: PubMed


Tobacco use among cancer patients is associated with adverse health outcomes. Little attention has been paid to tobacco use among cancer patients in developing countries, including Russia, where tobacco use is extremely high, and there is little public health infrastructure to address this issue.
This study examined medical, socio-demographic, and psychological correlates of smoking status and intention to quit smoking among newly diagnosed Russian cancer patients.
A cross-sectional study was conducted with 294 current or former smokers newly diagnosed with cancer.
Compared with patients who quit smoking, patients who continued to smoke were more likely to report urges to smoke to satisfy positive reinforcing aspects of tobacco use. Compared with patients who were smoking and reported no intention to quit smoking in the next 3 months, patients who were smoking but intended to quit smoking reported higher levels of perceived risks associated with continued smoking and higher levels of self-efficacy to quit smoking.
As commitment to developing smoking cessation treatment programs for cancer patients in Russia emerges, these data can help guide the development of behavioral interventions to assist patients with quitting smoking, enhancing their chances for improved clinical outcomes.

10 Reads
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The current special issue of IJBM on cancer includes six papers that provide excellent contemporary examples of how behavioral medicine research can be applied to the multiple missions of comprehensive cancer prevention and control. The work presented in each of these papers uses a diverse collection of populations, is solidly grounded in theory, and produces multiple insights that are relevant for public health consideration as well as clinical psychooncology practices. Among the many take-home messages from this collection are: (a) the great need to broaden behavioral medicine research in cancer to countries that have the greatest morbidity and mortality from the disease; (b) the importance and utility of considering the cultural relevance of psychosocial and behavior constructs adapted from health behavior change models; (c) the value of examining underlying biobehavioral and psychosocial mechanisms that can be used to adapt and target interventions; and (d) the mandate to conduct effectiveness trials of those primary, secondary, tertiary, and quaternary prevention interventions that have proven efficacious in controlled settings. All of these considerations will contribute to the successful dissemination of this innovative line of behavioral medicine research in the years to come.
    International Journal of Behavioral Medicine 12/2011; 18(4):288-92. DOI:10.1007/s12529-011-9200-7 · 2.63 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: INTRODUCTION: Understanding factors that render some individuals more vulnerable to smoking relapse during the early stages of a quit attempt is critical to tailoring treatment efforts. Development of laboratory models of relapse can provide a framework for identifying underlying mechanisms that may contribute to vulnerability. Here, we explored predictors of abstinence in a novel incentive-based model of relapse. METHODS: Fifty-six nontreatment seeking daily smokers completed several nicotine dependence measures prior to participating in a 1-week abstinence incentive test. During the abstinence procedure, participants earned monetary reinforcement for each biochemically verified day of abstinence according to a descending schedule of reinforcement. RESULTS: Compliance with the procedure was excellent. All but 3 participants were able to initiate abstinence; nearly 70% lapsed as incentives were reduced. Scores on the Fagerström Test for Nicotine Dependence (FTND), number of cigarettes smoked per day, and self-reported craving on the first day of abstinence each independently predicted time to lapse. The single item of time to first cigarette in the morning on the FTND significantly predicted time to lapse, even when controlling for other significant predictors just listed. The Nicotine Dependence Syndrome Scale (NDSS) and Wisconsin Inventory of Smoking Dependence Motives did not predict lapse, but the NDSS did predict reinitiation of abstinence among those experiencing an initial lapse.Conclusions:These findings partially replicate those of previous full-scale clinical trials and support the feasibility and validity of an incentive-based model of relapse. The time-limited and laboratory-based nature of this model has the potential to further investigations of underlying mechanisms contributing to relapse.
    Nicotine & Tobacco Research 04/2012; 15(1). DOI:10.1093/ntr/nts080 · 3.30 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Background: Smoking among Russian cancer patients may be related to variations in the DRD2/ANKK1 (Taq1), DRD4 (exon III VNTR), and SLC6A3 genes. Methods: Seven hundred fifty patients provided smoking history and DNA. Results: Current smokers were more likely to be DRD2 A2 allele carriers versus nonsmokers (former/never smokers; 69 vs. 56%; OR = 1.69; 95% CI 1.13-2.53, p = 0.01) and former smokers (69 vs. 59%; OR = 1.54; 95% CI 0.97-2.46, p = 0.07). Ever smokers (current/former smokers) were more likely to be DRD2 A2 allele carriers versus never smokers (65 vs. 55%; OR = 1.50; 95% CI 1.00-2.27, p = 0.05). The risk of current smoking among DRD2 A2 allele carriers was present if the DRD4 short allele was also present (OR = 1.76; 95% CI 1.12-2.78, p = 0.02), and the risk of ever smoking among DRD2 A2 allele carriers was present if the DRD4 short allele was also present (OR = 1.62; 95% CI 1.02-2.55, p = 0.04). DRD2 A2 allele carriers had a shorter period of previous abstinence versus DRD2 A1 carriers (p = 0.02). Effects were not statistically significant when controlling for multiple comparisons. Conclusions: The DRD2 A2 allele may increase the risk of smoking among cancer patients, convergent with studies using non-Western samples. However, additional replication is needed.
    European Addiction Research 11/2012; 19(2):105-111. DOI:10.1159/000341711 · 2.10 Impact Factor


10 Reads
Available from